Contenido

Síguenos en…

Síguenos en Facebook. Pulsando en este enlace estarás saliendo de hvn.es   Síguenos en Twitter. Pulsando en este enlace estarás saliendo de hvn.es

Síguenos en YouTube. Pulsando en este enlace estarás saliendo de hvn.es   Feed de noticias

Publicaciones

Publicaciones (2013/2018)

  • R. Pérez-Robles, L. Cuadros-Rodríguez, A. Salmerón-García, N. Navas. Development and validation of a (RP)UHPLC-UV-(HESI/Orbitrap)MS method for the identification and quantification of mixtures of intact therapeutical monoclonal antibodies using a monolithic column.. Journal of pharmaceutical and biomedical analysis. 2018 159: pp. 437 - 448. FI: 2.831 Q2 D4. (doi:10.1016/j.jpba.2018.07.013 PMID:30071467)
  • Á. Caballero Romero, MT. Delgado Ureña, A. Salmerón García, MT. Megías Fernández, M. Librada Porriño-Bustamante, J. Cabeza Barrera. Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes.. Anti-cancer drugs. 2018 29(9): pp. 821 - 826 (doi:10.1097/CAD.0000000000000672 PMID:30036190)
  • J. Hernández-Jiménez, A. Martínez-Ortega, A. Salmerón-García, J. Cabeza, JC. Prados, R. Ortíz, N. Navas. Study of aggregation in therapeutic monoclonal antibodies subjected to stress and long-term stability tests by analyzing size exclusion liquid chromatographic profiles.. International journal of biological macromolecules. 2018 118(Pt A): pp. 511 - 524. FI: 3.909. (doi:10.1016/j.ijbiomac.2018.06.105 PMID:29944945)
  • A. Martínez-Ortega, A. Herrera, A. Salmerón-García, J. Cabeza, L. Cuadros-Rodríguez, N. Navas. Validated reverse phase HPLC diode array method for the quantification of intact bevacizumab, infliximab and trastuzumab for long-term stability study.. International journal of biological macromolecules. 2018 116: pp. 993 - 1003. FI: 3.909 Q1 D2. (doi:10.1016/j.ijbiomac.2018.05.142 PMID:29792967)
  • G. Jiménez-Guerra, V. Heras-Cañas, M. Gutiérrez-Soto, M. Del Pilar Aznarte-Padial, M. Expósito-Ruiz, JM. Navarro-Marí, J. Gutiérrez-Fernández. Urinary tract infection by Acinetobacter baumannii and Pseudomonas aeruginosa: evolution of antimicrobial resistance and therapeutic alternatives.. Journal of medical microbiology. 2018 (doi:10.1099/jmm.0.000742 PMID:29693543)
  • C. Pérez-Ramírez, M. Cañadas-Garre, A. Alnatsha, E. Villar, J. Valdivia-Bautista, MJ. Faus-Dáder, MÁ. Calleja-Hernández. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients.. The pharmacogenomics journal. 2018. FI: 3.812. (doi:10.1038/s41397-018-0014-8 PMID:29662106)
  • C. Cuenca-Barrales, D. López-Delgado, B. Cáncela-Díez, M. Galvez-Moreno, R. Ruiz-Villaverde. Gray-bluish cutaneous pigmentation and ice-pick scars induced by vandetanib therapy.. International journal of dermatology. 2018 57(7): pp. e33 - e34. FI: 1.541. (doi:10.1111/ijd.13980 PMID:29638004)
  • C. Pérez-Ramírez, M. Cañadas-Garre, A. Alnatsha, E. Villar, JR. Delgado, MÁ. Calleja-Hernández, MJ. Faus-Dáder. Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer.. Pathology, research and practice. 2018 214(1): pp. 44 - 52 (doi:10.1016/j.prp.2017.11.015 PMID:29254785)
  • RC. Andrés, BC. Helena, PP. Juliana, AM. Viviana, GB. Margarita, CG. Marisa. Diabetes-related neurological implications and pharmacogenomics.. Current pharmaceutical design. 2018 24(15): pp. 1695 - 1710 D5. (doi:10.2174/1381612823666170317165350 PMID:28322157)
  • M. Maldonado-Montoro, M. Cañadas-Garre, A. González-Utrilla, M. Ángel Calleja-Hernández. Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis.. The pharmacogenomics journal. 2018 18(1): pp. 167 - 172. FI: 3.812. (doi:10.1038/tpj.2016.88 PMID:27958380)
  • A. Madrid-Paredes, M. Cañadas-Garre, A. Sánchez-Pozo, M. Expósito-Ruiz, MÁ. Calleja-Hernández. ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis.. Surgical oncology. 2017 26(4): pp. 473 - 482. FI: 2.558 Q2 D5. (doi:10.1016/j.suronc.2017.09.004 PMID:29113667)
  • A. Corma-Gómez, R. López-Sepúlveda, I. Capitán-Del Río, MD. Sánchez Mariscal, B. López-Hernández. [Consumption of psychoactive drugs and exposure to bacterial toxins carried by food: a dangerous association].. Gaceta sanitaria. 2017 D6. (doi:10.1016/j.gaceta.2017.08.003 PMID:29102506)
  • C. Pérez-Ramírez, A. Alnatsha, M. Cañadas-Garre, E. Villar, J. Valdivia-Bautista, MJ. Faus-Dáder, MÁ. Calleja-Hernández. Cytokine single-nucleotide polymorphisms and risk of non-small-cell lung cancer.. Pharmacogenetics and genomics. 2017 27(12): pp. 438 - 444 D5. (doi:10.1097/FPC.0000000000000307 PMID:28930110)
  • R. Ríos-Tamayo, A. Martín-García, C. Alarcón-Payer, D. Sánchez-Rodríguez, AMDVD. de la Guardia, CG. García Collado, A. Jiménez Morales, M. Jurado Chacón, J. Cabeza Barrera. Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.. Drug design, development and therapy. 2017 11: pp. 2399 - 2408. FI: 2.935 Q2 D4. (doi:10.2147/DDDT.S115456 PMID:28860711)
  • C. Pérez-Ramírez, M. Cañadas-Garre, A. Alnatsha, MÁ. Molina, AI. Robles, E. Villar, JR. Delgado, MJ. Faus-Dáder, MÁ. Calleja-Hernández. Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer.. Surgical oncology. 2017 26(3): pp. 278 - 285. FI: 2.558 Q2 D5. (doi:10.1016/j.suronc.2017.05.004 PMID:28807247)
  • L. Puig, J. Notario, A. Jiménez-Morales, MR. David, A. Lopez-Ferrer, I. Gozalbo, M. Prades, L. Lizán, C. Blanch. Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service.. The Journal of dermatological treatment. 2017 28(7): pp. 623 - 630 D5. (doi:10.1080/09546634.2017.1364687 PMID:28784002)
  • C. Pérez-Ramírez, M. Cañadas-Garre, MÁ. Molina, AI. Robles, MJ. Faus-Dáder, MÁ. Calleja-Hernández. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.. Mutation research. 2017 771: pp. 32 - 58 D2. (doi:10.1016/j.mrrev.2016.11.003 PMID:28342452)
  • R. López-Sepúlveda, MÁ. García Lirola, E. Espínola García, JM. Jurado Martínez, S. Martín Sances, S. Anaya Ordóñez, J. Cabeza Barrera. Antidiabetic medications use trends in an Andalusian region from 2001 to 2014.. Primary care diabetes. 2017 11(3): pp. 254 - 264 D6. (doi:10.1016/j.pcd.2017.01.003 PMID:28126469)
  • CL. Dávila-Fajardo, J. Sánchez-Ramos, XD. Villamarín, LJ. Martínez-González, PT. Frías, SM. Huertas, FB. Gómez, JC. Borrego, AB. Pavés, MC. Guzmán, JA. Hernández, CC. Vilches, JC. Barrera. The study protocol for a non-randomized controlled clinical trial using a genotype-guided strategy in a dataset of patients who undergone percutaneous coronary intervention with stent.. Data in brief. 2017 10: pp. 518 - 524 (doi:10.1016/j.dib.2016.12.019 PMID:28066799)
  • MÁ. Calleja Hernández, A. Herrero Ambrosio, MJ. Lamas Díaz, J. Martínez Cutillas, JL. Poveda Andrés, B. Aragón. Pharmacotherapy follow-up of patients under treatment with biologic agents for chronic inflammatory systemic conditions: an agreement among hospital pharmacists for the standardized collection of a minimum set of data.. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2017 41(n01): pp. 31 - 48 (doi:10.7399/fh.2017.41.1.10463 PMID:28045651)
  • R. López-Sepúlveda, MÁ. García Lirola, E. Espínola García, S. Martín Sances, S. Anaya Ordóñez, JM. Jurado Martínez, J. Cabeza Barrera. Effects of a primary care intervention to improve the quality of zolpidem prescriptions in elderly patients.. European journal of clinical pharmacology. 2017 73(4): pp. 455 - 461 D4. (doi:10.1007/s00228-016-2180-4 PMID:28028585)
  • CH. van der Wouden, A. Cambon-Thomsen, E. Cecchin, KC. Cheung, C. Lucía Dávila-Fajardo, VH. Deneer, V. Dolžan, M. Ingelman-Sundberg, S. Jönsson, MO. Karlsson, M. Kriek, C. Mitropoulou, GP. Patrinos, M. Pirmohamed, M. Samwald, E. Schaeffeler, M. Schwab, D. Steinberger, J. Stingl, G. Sunder-Plassmann, G. Toffoli, RM. Turner, MH. van Rhenen, JJ. Swen, HJ. Guchelaar. Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.. Clinical pharmacology and therapeutics. 2017 101(3): pp. 341 - 358 D1. (doi:10.1002/cpt.602 PMID:28027596)
  • EA. Domingues, M. Ferrit-Martín, MÁ. Calleja-Hernández. Impact of pharmaceutical care on cardiovascular risk among older HIV patients on antiretroviral therapy.. International journal of clinical pharmacy. 2017 39(1): pp. 52 - 60 D8. (doi:10.1007/s11096-016-0387-1 PMID:27864732)
  • S. Arenas-López, IM. Stanley, P. Tunstell, V. Aguado-Lorenzo, J. Philip, J. Perkins, A. Durward, MA. Calleja-Hernández, SM. Tibby. Safe implementation of standard concentration infusions in paediatric intensive care.. The Journal of pharmacy and pharmacology. 2017 69(5): pp. 529 - 536 D6. (doi:10.1111/jphp.12580 PMID:27334458)
  • . . CP-160 Carbapenem de-escalation therapy for intra-abdominal infection. European Journal of Hospital Pharmacy. 2017 4(Sup 1). FI: 0.538 Q4 D1.
  • A. Martínez-Ortega, A. Herrera, A. Salmerón-García, J. Cabeza, L. Cuadros-Rodríguez, N. Navas. Study and ICH validation of a reverse-phase liquid chromatographic method for the quantification of the intact monoclonal antibody cetuximab.. Journal of pharmaceutical analysis. 2016 6(2): pp. 117 - 124 (doi:10.1016/j.jpha.2015.11.007 PMID:29403971)
  • V. Torres-Degayón, FJ. Montero-Pérez, JM. Torres-Murillo, MJ. Faus-Dáder, MI. Baena-Parejo, MA. Calleja-Hernández. [Medication-related negative outcomes in patients with permanent atrial fibrillation attended in a hospital emergency department].. Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias. 2016 28(2): pp. 75 - 82 ( PMID:29105427)
  • MA. Pérez-Moreno, J. Cotrina-Luque, M. Galván-Banqueri, S. Flores-Moreno, FJ. Bautista-Paloma, MÁ. Calleja-Hernández. Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System.. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2016 40(n06): pp. 477 - 485 (doi:10.7399/fh.2016.40.6.10424 PMID:27894221)
  • C. Pérez-Ramírez, M. Cañadas-Garre, AI. Robles, MÁ. Molina, MJ. Faus-Dáder, MÁ. Calleja-Hernández. Liquid biopsy in early stage lung cancer.. Translational lung cancer research. 2016 5(5): pp. 517 - 524 (doi:10.21037/tlcr.2016.10.15 PMID:27826533)
  • J. Sánchez-Ramos, CL. Dávila-Fajardo, P. Toledo Frías, X. Díaz Villamarín, LJ. Martínez-González, S. Martínez Huertas, F. Burillo Gómez, J. Caballero Borrego, A. Bautista Pavés, MC. Marín Guzmán, JA. Ramirez Hernández, C. Correa Vilches, J. Cabeza Barrera. Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent.. International journal of cardiology. 2016 225: pp. 289 - 295. FI: 4.638 Q1. (doi:10.1016/j.ijcard.2016.09.088 PMID:27744205)
  • J. Pasquau, S. Sadyrbaeva, SE. De Jesús, C. Hidalgo-Tenorio. [The role of antimicrobial stewardship programs in the control of bacterial resistance].. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia. 2016 29 Suppl 1: pp. 47 - 51. FI: 1.014 Q4. ( PMID:27608314)
  • TM. Linares Pineda, M. Cañadas-Garre, MÁ. Calleja-Hernández. GENE POLYMORPHISMS AS PREDICTORS OF RESPONSE TO BIOLOGICAL THERAPIES IN PSORIASIS PATIENTS.. Pharmacological research. 2016 113(Pt A): pp. 71 - 80. FI: 4.816 Q1. (doi:10.1016/j.phrs.2016.07.020 PMID:27524442)
  • MÁ. Allende-Bandrés, F. Ruiz-Laiglesia, F. Gutiérrez-Nicolás, MÁ. Calleja Hernández. Patient safety: The pharmacist's contribution to a multidisciplinary Internal Medicine patient-care team.. Revista clinica espanola. 2016 216(9): pp. 510 - 512. FI: 0.76 Q3. (doi:10.1016/j.rce.2016.07.001 PMID:27499226)
  • C. Pérez-Ramírez, M. Cañadas-Garre, A. Alnatsha, E. Villar, JR. Delgado, MJ. Faus-Dáder, MÁ. Calleja-Hernández. PHARMACOGENETIC PREDICTORS OF TOXICITY TO PLATINUM BASED CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER PATIENTS.. Pharmacological research. 2016 111: pp. 877 - 884. FI: 4.816 Q1. (doi:10.1016/j.phrs.2016.08.002 PMID:27498158)
  • X. Díaz-Villamarín, CL. Dávila-Fajardo, LJ. Martínez-González, P. Carmona-Sáez, J. Sánchez-Ramos, MJ. Álvarez Cubero, LM. Salmerón-Febres, J. Cabeza Barrera, F. Fernández-Quesada. Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty.. Pharmacogenomics. 2016 17(12): pp. 1327 - 1338. FI: 2.71 Q2. (doi:10.2217/pgs-2016-0056 PMID:27464309)
  • M. Maldonado-Montoro, M. Cañadas-Garre, A. González-Utrilla, JC. Plaza-Plaza, MÁ. Calleja-Hernández. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis.. Pharmacological research. 2016 111: pp. 264 - 271. FI: 4.816 Q1. (doi:10.1016/j.phrs.2016.06.016 PMID:27339827)
  • M. Cañadas-Garre, P. Becerra-Massare, A. Moreno Casares, MÁ. Calleja-Hernández, JM. Llamas-Elvira. Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas.. Head & neck. 2016 38(12): pp. 1772 - 1779. FI: 2.76 Q1. (doi:10.1002/hed.24517 PMID:27299298)
  • I. Suárez, A. Salmerón-García, J. Cabeza, LF. Capitán-Vallvey, N. Navas. Development and use of specific ELISA methods for quantifying the biological activity of bevacizumab, cetuximab and trastuzumab in stability studies.. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2016 1032: pp. 155 - 164. FI: 2.687 Q2. (doi:10.1016/j.jchromb.2016.05.045 PMID:27296731)
  • A. Madrid-Paredes, M. Cañadas-Garre, A. Sánchez-Pozo, AM. Segura-Pérez, CC. Santos, EV. Alcaide, LC. Portellano, MÁ. Calleja-Hernández. ABCB1 C3435T GENE POLYMORPHISM AS A POTENTIAL BIOMARKER OF CLINICAL OUTCOMES IN HER2-POSITIVE BREAST CANCER PATIENTS.. Pharmacological research. 2016 108: pp. 111 - 118. FI: 4.816 Q1. (doi:10.1016/j.phrs.2016.04.016 PMID:27137881)
  • MA. Moles, JA. Montoya, MD. Salvago, IR. Ávila, JJ. Campillo, M. Bravo. Implications of Differential Expression of β-Catenin in Oral Carcinoma.. Anticancer research. 2016 36(4): pp. 1599 - 1604. FI: 1.895 Q3. ( PMID:27069136)
  • HY. Tong, CL. Dávila-Fajardo, AM. Borobia, LJ. Martínez-González, R. Lubomirov, LM. Perea León, MJ. Blanco Bañares, X. Díaz-Villamarín, C. Fernández-Capitán, J. Cabeza Barrera, AJ. Carcas. A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population.. PloS one. 2016 11(3): pp. e0150456 - e0150456. FI: 3.057 Q1. (doi:10.1371/journal.pone.0150456 PMID:26977927)
  • J. Hernández-Jiménez, A. Salmerón-García, J. Cabeza, C. Vélez, LF. Capitán-Vallvey, N. Navas. The Effects of Light-Accelerated Degradation on the Aggregation of Marketed Therapeutic Monoclonal Antibodies Evaluated by Size-Exclusion Chromatography With Diode Array Detection.. Journal of pharmaceutical sciences. 2016 105(4): pp. 1405 - 1418. FI: 2.641 Q2. (doi:10.1016/j.xphs.2016.01.012 PMID:26952878)
  • AJ. Pardo Cabello, E. Del Pozo Gavilán, FJ. Gómez Jiménez, C. Mota Rodríguez, JD. Luna Del Castillo, E. Puche Cañas. Drug-related mortality among inpatients: a retrospective observational study.. European journal of clinical pharmacology. 2016 72(6): pp. 731 - 736. FI: 2.71 Q2. (doi:10.1007/s00228-016-2026-0 PMID:26896941)
  • F. Mesa, E. Pozo, F. O'Valle, A. Puertas, A. Magan-Fernandez, E. Rosel, M. Bravo. Relationship between periodontal parameters and plasma cytokine profiles in pregnant woman with preterm birth or low birth weight.. Clinical oral investigations. 2016 20(4): pp. 669 - 674. FI: 2.207 Q1. (doi:10.1007/s00784-015-1553-x PMID:26245274)
  • L. González-García, A. Salmerón-García, MA. García-Lirola, S. Moya-Roldán, S. Belda-Rustarazo, J. Cabeza-Barrera. Medication reconciliation at admission to surgical departments.. Journal of evaluation in clinical practice. 2016 22(1): pp. 20 - 25. FI: 1.053 Q3. (doi:10.1111/jep.12403 PMID:26083630)
  • C. Piqueras Romero, B. Calderón Hernanz, A. Segura Fragoso, R. Juárez González, MA. Berrocal Javato, MÁ. Calleja Hernández. [NEfficacy of a reconciliation intervention by a specialized pharmacist to resolve medication-related problems of elderly patients admitted to an emergency department short-stay unit: a randomized clinical trial].. Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias. 2015 27(6): pp. 364 - 370 ( PMID:29094837)
  • C. Pérez-Ramírez, M. Cañadas-Garre, MÁ. Molina, MJ. Faus-Dáder, MÁ. Calleja-Hernández. PTEN and PI3K/AKT in non-small-cell lung cancer.. Pharmacogenomics. 2015 16(16): pp. 1843 - 1862. FI: 2.71 Q2. (doi:10.2217/pgs.15.122 PMID:26555006)
  • P. Siquier Homar, M. Pinteño Blanco, MÁ. Calleja Hernández, F. Fernández Cortés, J. Martínez Sotelo. Development of integrated support software for clinical nutrition.. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2015 39(n05): pp. 240 - 268 (doi:10.7399/fh.2015.39.5.8807 PMID:26546938)
  • C. Pérez-Ramírez, M. Cañadas-Garre, MÁ. Molina, MJ. Faus-Dáder, MÁ. Calleja-Hernández. MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer.. Pharmacological research. 2015 102: pp. 90 - 106. FI: 4.816 Q1 3. (doi:10.1016/j.phrs.2015.09.016 PMID:26413995)
  • A. Madrid-Paredes, M. Cañadas-Garre, A. Sánchez-Pozo, MÁ. Calleja-Hernández. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.. Breast cancer research and treatment. 2015 153(3): pp. 493 - 505. FI: 4.085 Q2 7. (doi:10.1007/s10549-015-3578-x PMID:26400847)
  • J. Córdoba, NM. Coronado-Álvarez, D. Parra, J. Parra-Ruiz. In Vitro Activity of Novel Antimicrobial Combinations against Extensively drug-resistant Acinetobacter baumannii.. Antimicrobial agents and chemotherapy. 2015 59(12): pp. 7316 - 7319. FI: 4.415 Q1. (doi:10.1128/AAC.00493-15 PMID:26369956)
  • R. Ríos-Tamayo, MJ. Sánchez, JM. Puerta, J. Sáinz, DY. Chang, T. Rodríguez, P. López, JM. de Pablos, P. Navarro, JL. de Veas, A. Romero, P. Garrido, L. Moratalla, C. Alarcón-Payer, E. López-Fernández, PA. González, JJ. Jiménez-Moleón, MÁ. Calleja-Hernández, M. Jurado. Trends in survival of multiple myeloma: A thirty-year population-based study in a single institution.. Cancer epidemiology. 2015 39(5): pp. 693 - 699. FI: 2.644 Q3 4. (doi:10.1016/j.canep.2015.08.002 PMID:26277330)
  • R. Morillo Verdugo, J. Sáez de la Fuente, MÁ. Calleja Hernandez. [MAPEX: look deeper, looking away].. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 2015 39(4): pp. 189 - 191 (doi:10.7399/fh.2015.39.4.9407 PMID:26276736)
  • A. Madrid-Paredes, M. Cañadas-Garre, A. Sánchez-Pozo, MÁ. Calleja-Hernández. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.. Pharmacogenomics. 2015 16(12): pp. 1411 - 1426. FI: 2.71 Q2. (doi:10.2217/pgs.15.88 PMID:26257318)
  • E. Puerta-García, M. Cañadas-Garre, MÁ. Calleja-Hernández. Molecular biomarkers in colorectal carcinoma.. Pharmacogenomics. 2015 16(10): pp. 1189 - 1222. FI: 2.71 Q2 7. (doi:10.2217/PGS.15.63 PMID:26237292)
  • S. Belda-Rustarazo, J. Cantero-Hinojosa, A. Salmeron-García, L. González-García, J. Cabeza-Barrera, J. Galvez. Medication reconciliation at admission and discharge: an analysis of prevalence and associated risk factors.. International journal of clinical practice. 2015 69(11): pp. 1268 - 1274. FI: 2.226 Q1. (doi:10.1111/ijcp.12701 PMID:26202091)
  • P. García-Martín, C. Alarcón-Payer, E. López-Fernández, L. Moratalla, A. Romero, J. Sainz, R. Ríos, M. Jurado. Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.. The Annals of pharmacotherapy. 2015 49(9): pp. 986 - 994. FI: 2.119 Q3 14. (doi:10.1177/1060028015593369 PMID:26160968)
  • E. Jiménez-Varo, M. Cañadas-Garre, V. Garcés-Robles, MJ. Gutiérrez-Pimentel, MÁ. Calleja-Hernández. Extrapolation of acenocoumarol pharmacogenetic algorithms.. Vascular pharmacology. 2015 74: pp. 151 - 157. FI: 2.5 Q2. (doi:10.1016/j.vph.2015.06.010 PMID:26122664)
  • A. Lozano-Blázquez, R. Dickson, MD. Fraga-Fuentes, F. Martínez-Martínez, MÁ. Calleja-Hernández. Differences in cancer drug assessment between Spain and the United Kingdom.. European journal of cancer (Oxford, England : 1990). 2015 51(13): pp. 1843 - 1852. FI: 6.163 Q1 3. (doi:10.1016/j.ejca.2015.04.022 PMID:26119375)
  • CGP. GOMEZ-PEÑA, CLDF. DAVILA-FAJARDO, LJMG. MARTINEZ-GONZALEZ, PCS. CARMONA-SAEZ, MJSP. SOTO-PINO, JSR. SANCHEZ-RAMOS, EME. MORENO-ESCOBAR, IB. BLANCAS, JJF. FERNANDEZ, DF. FERNANDEZ, CCV. CORREA-VILCHES, JCB. CABEZA-BARRERA. Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients: a meta-analysis. Pharmacogenetics and genomics. 2015 25(8): pp. 388 - 393. FI: 2.857 Q2. (doi:10.1097/FPC.0000000000000149 PMID:26049584)
  • V. Torres-Degayón, JM. Torres-Murillo, MI. Baena-Parejo, MC. Muñoz-Villanueva, G. Montes-Redondo, MA. Calleja-Hernández, MJ. Faus-Dáder. Negative outcomes associated with medication in patients with chronic atrial fibrillation who present at the emergency department.. Journal of clinical pharmacy and therapeutics. 2015 40(4): pp. 452 - 460. FI: 1.833 Q3 18. (doi:10.1111/jcpt.12289 PMID:26032557)
  • J. Martinez-Cutillas, C. Alerany-Pardo, J. Borrás-Blasco, A. Broto-Sumalla, A. Burgos-SanJosé, C. Climent-Bolta, V. Escudero-Vilaplana, MA. Fernández-Fuente, M. Ferrit-Martin, P. Gómez-Germá, JM. Martínez-Sesmero, J. Mayorga-Pérez, B. Menchén-Viso, J. Merino-Alonso, J. Polache-Vengud, A. Sánchez-Guerrero. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.. Expert review of pharmacoeconomics & outcomes research. 2015 15(5): pp. 851 - 858. FI: 1.631 Q3 5. (doi:10.1586/14737167.2015.1044514 PMID:25972066)
  • C. Pérez-Ramírez, M. Cañadas-Garre, E. Jiménez-Varo, MJ. Faus-Dáder, MÁ. Calleja-Hernández. MET: a new promising biomarker in non-small-cell lung carcinoma.. Pharmacogenomics. 2015 16(6): pp. 631 - 647. FI: 2.71 Q2. (doi:10.2217/pgs.15.11 PMID:25893986)
  • CLDF. DAVILA-FAJARDO, TVDS. VAN DER STRAATEN, RBP. BAAK-PABLO, CMC. MEDARDE-CABALLERO, JCB. CABEZA-BARRERA, TWH. HUIZINGA, HJG. GUCHELAAR, JJS. SWEN. FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. Pharmacogenomics. 2015 16(4): pp. 373 - 381. FI: 2.71 Q2. (doi:10.2217/pgs.14.178 PMID:25823785)
  • A. Marín Armero, MA. Calleja Hernandez, S. Perez-Vicente, F. Martinez-Martinez. Pharmaceutical care in smoking cessation.. Patient preference and adherence. 2015 9: pp. 209 - 215. FI: 1.718 Q2 8. (doi:10.2147/PPA.S67707 PMID:25678779)
  • J. Turnes, R. Díaz, M. Hernandez-Guerra, M. Gómez, L. Castells, J. Bustamante, MD. Espinosa, J. Fernández-Castroagudín, T. Serrano, P. Rendón, R. Andrade, M. Salgado, J. Arenas, M. Vergara, M. Sala, BA. Polo, IM. Granizo, ML. Gonzálvez, A. Viudez. Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain.. Gastroenterologia y hepatologia. 2015 38(4): pp. 263 - 273. FI: 0.8 Q4 7. (doi:10.1016/j.gastrohep.2014.11.001 PMID:25583146)
  • MI. Baena Parejo, AM. Juanes Borrego, JA. Ruiz, MC. Monjó, M. García-Peláez, BC. Hernanz, MÁ. Calleja Hernández, MI. Chinchilla Fernández, MP. Riera, RG. Sánchez, LG. Sánchez, CV. López, MD. Mauleon Echeverria, PM. Serrano. Medication List Assessment in Spanish Hospital Emergency Departments.. The Journal of emergency medicine. 2015 48(4): pp. 416 - 423. FI: 1.048 Q3. (doi:10.1016/j.jemermed.2014.06.063 PMID:25547811)
  • C. Gastalver-Martín, C. Alarcón-Payer, M. León-Sanz. Individualized measurement of disease-related malnutrition's costs.. Clinical nutrition (Edinburgh, Scotland). 2015 34(5): pp. 951 - 955. FI: 4.487 Q1. (doi:10.1016/j.clnu.2014.10.005 PMID:25456609)
  • S. Cortés de Miguel, MA. Calleja-Hernández, S. Menjón-Beltrán, I. Vallejo-Rodríguez. Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2015 23(2): pp. 547 - 559. FI: 2.535 Q2 1. (doi:10.1007/s00520-014-2459-x PMID:25284722)
  • AJ. Sastre-Heres, MA. Calero, D. Ruiz-Sánchez, MT. García, MA. Hernandez, FM. Martínez, J. Peña-Díaz. Study of the effectiveness of first-line treatment in renal cell carcinoma.. Molecular and clinical oncology. 2014 2(6): pp. 1167 - 1171 (doi:10.3892/mco.2014.353 PMID:25279217)
  • E. Jiménez-Varo, M. Cañadas-Garre, MJ. Gutiérrez-Pimentel, MA. Calleja-Hernández. Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm.. Pharmacogenetics and genomics. 2014 24(10): pp. 501 - 513. FI: 3.608. (doi:10.1097/FPC.0000000000000082 PMID:25089947)
  • A. Lozano-Blázquez, C. Calvo-Pita, M. Carbajales-Álvarez, P. Suárez-Gil, F. Martínez-Martínez, MÁ. Calleja-Hernández. Drug assessment by a Pharmacy and Therapeutics committee: From drug selection criteria to use in clinical practice. Therapeutics and clinical risk management. 2014 10(1): pp. 527 - 535. FI: 1.469. (doi:10.2147/TCRM.S62572 PMID:25031538)
  • E. Jiménez-Varo, M. Cañadas-Garre, CI. Henriques, AM. Pinheiro, MJ. Gutiérrez-Pimentel, MÁ. Calleja-Hernández. Pharmacogenetics role in the safety of acenocoumarol therapy.. Thrombosis and haemostasis. 2014 112(3): pp. 522 - 536. FI: 4.984. (doi:10.1160/TH13-11-0941 PMID:24919870)
  • R. Ortega, A. Salmerón-García, J. Cabeza, LF. Capitán-Vallvey, N. Navas. Stability of daptomycin 5 mg/mL and heparin sodium 100 units/mL combined in lactated Ringer's injection and stored in polypropylene syringes at 4 and -20°C.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2014 71(11): pp. 956 - 959. FI: 1.882. (doi:10.2146/ajhp130481 PMID:24831000)
  • S. Manrique-Rodríguez, AC. Sánchez-Galindo, J. López-Herce, MA. Calleja-Hernández, I. Iglesias-Peinado, A. Carrillo-Álvarez, MS. Sáez, CM. Fernández-Llamazares. Risks in the implementation and use of smart pumps in a pediatric intensive care unit: Application of the failure mode and effects analysis. International journal of technology assessment in health care. 2014 30(2): pp. 1 - 8. FI: 1.551 3 2. (doi:10.1017/S0266462314000051 PMID:24773916)
  • A. Montes, CLDF. DAVILA-FAJARDO, E. Perez-Pampin, J. Narváez, JD. Cañete, F. Navarro-Sarabia, V. Moreira, A. Fernández-Nebro, M. Del Carmen Ordóñez, AR. de la Serna, B. Magallares, Y. Vasilopoulos, T. Sarafidou, R. Caliz, MA. Ferrer, B. Joven, P. Carreira, JJ. Gómez-Reino, A. Gonzalez. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenetics and genomics. 2014 24(5): pp. 238 - 245. FI: 3.608 1 2. (doi:10.1097/FPC.0000000000000042 PMID:24667440)
  • R. López-Sepúlveda, C. Fernández-López, C. García Collado, A. Jiménez Morales, C. Valencia Soto, MÁ. Calleja Hernández. [Boceprevir and telaprevir safety in routine clinical practice].. Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria. 2014 38(1): pp. 44 - 49 ( PMID:24483859)
  • M. Cañadas-Garre, AM. Fernandez-Escamilla, G. Fernandez-Ballester, P. Becerra-Massare, C. García-Calvente, JL. Ramos, JM. Llamas-Elvira. Novel BRAFI599Ins Mutation Identified in a Follicular Variant of a Papillary Thyroid Carcinoma: A Molecular Modeling Approach.. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2014 20(5): pp. e75 - 79. FI: 2.811. (doi:10.4158/EP13465.CR PMID:24449679)
  • S. Manrique-Rodríguez, AC. Sánchez-Galindo, J. López-Herce, MÁ. Calleja-Hernández, F. Martínez-Martínez, I. Iglesias-Peinado, A. Carrillo-Álvarez, M. Sanjurjo-Sáez, CM. Fernández-Llamazares. Implementing smart pump technology in a pediatric intensive care unit: A cost-effective approach. International journal of medical informatics. 2014 83(2): pp. 99 - 105. FI: 2.061 1 1. (doi:10.1016/j.ijmedinf.2013.10.011 PMID:24296271)
  • CLDF. DAVILA-FAJARDO, AM. MARQUEZ, DPS. PASCUAL-SALCEDO, MJMR. MORENO-RAMOS, RGP. GARCIA-PORTALES, CMC. MAGRO-CHECA, JJAS. ALEGRE-SANCHO, AB. BALSA, JCB. CABEZA-BARRERA, ERA. RAYA-ALVAREZ, JM. MARTIN. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. Pharmacogenetics and genomics. 2014 24(1): pp. 1 - 5. FI: 3.608. (doi:10.1097/FPC.0000000000000013 PMID:24253594)
  • A. Márquez, A. Ferreiro Iglesias, CL. Dávila Fajardo, A. Montes, D. Pascual Salcedo, E. Perez Pampin, MJ. Moreno Ramos, R. García Portales, F. Navarro, V. Moreira, C. Magro, R. Caliz, MA. Ferrer, JJ. Alegre Sancho, B. Joven, P. Carreira, A. Balsa, Y. Vasilopoulos, T. Sarafidou, J. Cabeza Barrera, J. Narvaez, E. Raya, JD. Cañete, A. Fernández Nebro, MDC. Ordóñez, AR. De la Serna, B. Magallares, JJ. Gomez Reino, A. González, J. Martín. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: A genome-wide association study replication and meta-analysis. Arthritis Res. Ther.. 2014 16(2): pp. R66. FI: 4.302 1 1. (doi:10.1186/ar4504 )
  • R. López Sepúlveda, C. Fernández López, CG. Collado, AJ. Morales, CV. Soto, MÁC. Hernández. Boceprevir and telaprevir safety in routine clinical practice. Farm. Hosp.. 2014 38(1): pp. 44 - 49 (doi:10.7399/FH.2014.38.1.1142 )
  • L. Franco Trigo, MA. Calleja Hernández, JP. García Corpas. Treatment of febrile neutropenia: Filgrastim and pegfilgrastim. Ars Pharmaceutica. 2014 55(1): pp. 1 - 7
  • TS. Casanueva, JMT. Burillo, FM. Martínez, JCV. Gámez, EN. Maestre, MAC. Hernández. Effects of a pharmaceutical care program for patients with multiple sclerosis on immunomodulatory treatment adherence. Ars Pharmaceutica. 2014 55(1): pp. 37 - 44
  • S. Manrique-Rodríguez, AC. Sánchez-Galindo, J. López-Herce, MA. Calleja-Hernández, F. Martínez-Martínez, I. Iglesias-Peinado, A. Carrillo-Álvarez, MS. Sáez, CM. Fernández-Llamazares. Impact of implementing smart infusion pumps in a pediatric intensive care unit.. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2013 70(21): pp. 1897 - 1906. FI: 1.984 3 15. (doi:10.2146/ajhp120767 PMID:24128965)
  • CLDF. DAVILA-FAJARDO, JJS. SWEN, JCB. CABEZA-BARRERA, HJG. GUCHELAAR. Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate. Pharmacogenomics. 2013 14(1): pp. 63 - 73. FI: 3.425. (doi:10.2217/pgs.12.183 PMID:23252949)
  • MA. Calleja, JM. Vieites, T. Montero-Meterdez, MI. Torres, MJ. Faus, A. Gil, A. Suárez. The antioxidant effect of β-caryophyllene protects rat liver from carbon tetrachloride-induced fibrosis by inhibiting hepatic stellate cell activation. The British journal of nutrition. 2013 109(3): pp. 394 - 401. FI: 3.302 1 2. (doi:10.1017/S0007114512001298 PMID:22717234)
  • C. Alarcón Payer, A. Jiménez Morales, A. Del Saz Caracuel, MÁC. Hernández. Effectiveness and safety of sodium oxybate in narcolepsy-cataplexy syndrome. Euro. J. Hosp. Pharm. Sci. Pra.. 2013 20(1): pp. 32 - 35. FI: 0.471. (doi:10.1136/ejhpharm-2012-000122 )
  • AS. Díaz, JS. De La Fuente, L. Esteva, AMA. Pardo, N. Barrueco, C. Esteban, IE. Rodríguez. Drug prescribing in patients with renal impairment optimized by a computer-based, semi-automated system. Int. J. Clin. Pharm.. 2013 35(6): pp. 1170 - 1177. FI: 0.859. (doi:10.1007/s11096-013-9843-3 )
  • AM. Alañón Pardo, R. Ubago Pérez, MÁ. Calleja HernÁndez, P. Araque Arroyo, B. Candela Díez, M. Ferrit MartÍn. Adaptation of the chemotherapy prescription for breast cancer in a tertiary hospital. Impact on survival. Aten. Farm.. 2013 15(3): pp. 178 - 184. FI: 0.125 4 25.
  • MS. Legnoverde, I. Jiménez Morales, A. Jiménez Morales, E. Rodríguez Castellón, EI. Basaldella. Modified silica matrices for controlled release of cephalexin. Med. Chem.. 2013 9(5): pp. 672 - 680. FI: 1.373 4 4.
  • B. Cancela Díez, F. Gutiérrez Nicolás, P. Araque Arroyo, AM. Alañón Pardo, M. Salazar Bravo, MÁ. Calleja Hernández. Methotrexate monitoring in serum and cerebrospinal fluid (CSF) of patient with medulloblastoma. Aten. Farm.. 2013 15(2): pp. 128 - 130. FI: 0.125.
  • RM. Romero Jiménez, MA. Calleja Hernández, M. Chaparro Recio, F. Martínez Martínez, M. Sanjurjo Sáez. Effect of pharmacotherapy follow-up on treatment adherence and virologic and immune response in patients with human immunodeficiency virus. Lat. Am. J. Pharm.. 2013 32(3): pp. 441 - 447. FI: 0.244 4 25.
  • M. Heredia, JM. Tenías, R. Rocio, F. Amparo, MA. Calleja, JC. Valenzuela. Quality of life and predictive factors in patients undergoing assisted reproduction techniques. European journal of obstetrics, gynecology, and reproductive biology. 2013 167(2): pp. 176 - 180. FI: 1.627 2 3. (doi:10.1016/j.ejogrb.2012.12.011 )
  • RJ. Galán, EC. Cidoncha, MF. Martin, CC. Rodriguez, CVA. González, RM. Verdugo. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C. J. Managed Care Pharm.. 2013 19(6): pp. 448 - 453. FI: 2.414 1 2.
  • V. Martínez Santana, E. González Sarmiento, M. Calleja Hernández, T. Sánchez Sánchez. Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis. Patient Preference Adherence. 2013 pp. 719 - 727. FI: 1.333 2 6. (doi:10.2147/PPA.S47453 )
  • T. Sánchez Casanueva, JM. Tenías Burillo, F. Martínez Martínez, JC. Valenzuela Gámez, E. Navarro Maestre, MÁ. Calleja Hernández. Effects of a pharmaceutical care program for patients with multiple sclerosis on immunomodulatory treatment adherence. Ars Pharmaceutica. 2013 54(4): pp. 2 - 8
  • MAA. Bandres, MA. Mendoza, FG. Nicolás, MAC. Hernandez, FR. La Iglesia. Pharmacist-led medication reconciliation to reduce discrepancies in transitions of care in Spain. Int. J. Clin. Pharm.. 2013 35(6): pp. 1083 - 1090. FI: 0.859 4 21. (doi:10.1007/s11096-013-9824-6 )
  • M. Muros Ortega, MS. Díaz Carrasco, A. Capel, MA. Calleja, F. Martínez. Effectiveness and safety of doxorubicin loaded beads in hepatocellular carcinoma. Int. J. Clin. Pharm.. 2013 35(6): pp. 1105 - 1112. FI: 0.859 4 21. (doi:10.1007/s11096-013-9831-7 )
  • C. García Muñoz, C. Alarcón Payer, I. Cañamares Orbis, MJ. Jiménez Cerezo, JM. Ferrari Piquero, MA. Calleja Hernández. Therapeutic interchange programs in Spain and abroad. Aten. Farm.. 2013 15(4): pp. 279 - 285. FI: 0.125 4 25.
  • AM. MARQUEZ, CLDF. DAVILA-FAJARDO, GR. ROBLEDO, JLCR. CALLEJAS-RUBIO, ERG. DE RAMON GARRIDO, FJGH. GARCIA-HERNANDEZ, RGL. GONZALEZ-LEON, RRF. RIOS-FERNANDEZ, JCB. CABEZA-BARRERA, MFGE. GONZALEZ-ESCRIBANO, MTCG. CAMPS-GARCIA, MJCP. CASTILLO-PALMA, MMA. AYALA, NOC. ORTEGO-CENTENO, JM. MARTIN. IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients. Molecular Biology Reports. 2013 40(8): pp. 4851-6. FI: 1.958. (doi:10.1007/s11033-013-2583-6 )
Última actualización de datos: 16-10-2018
27.833.004 visitas desde el 1 de Marzo de 2006
Última actualización de la pagina: 24-07-2018 Subir
Certificación Emas Certificacion Responsabilidad Social Certificacion Gestión Ambiental Certificacion Seguridad Alimentaria Certificacion Salud Laboral
Las páginas del dominio hvn.es cumplen con las normas de accesibilidad WCAG 2.0 nivel AAA
hvn.es cumple con las normas de W3C para el lenguaje de marcado XHTML 1.0
hvn.es cumple con las normas de W3C para hojas de estilo
FIBAO IBS Logo de Green Light Logo de OMARS Logo de Living Lab Salud Andalucía Red de Comités de Ética del SSPA CEI Biotic - Granada
Datos de Contacto | Webmaster | Mapa web | Nota legal | Política editorial | Uso del sitio | Accesibilidad | Preguntas frecuentas | RSS
© 2003 - 2018. Hospital Universitario Virgen de las Nieves.
- HUVN -